| Erenumab in highly therapy-refractory migraine patients: first German real-world evidence A Scheffler, O Messel, S Wurthmann, M Nsaka, C Kleinschnitz, M Glas, ... The journal of headache and pain 21, 1-5, 2020 | 83 | 2020 |
| CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience A Scheffler, H Schenk, S Wurthmann, M Nsaka, C Kleinschnitz, M Glas, ... The Journal of Headache and Pain 22, 1-6, 2021 | 23 | 2021 |
| Sensitized rotatory motion perception and increased susceptibility to motion sickness in vestibular migraine: A cross‐sectional study S Wurthmann, S Naegel, M Roesner, M Nsaka, A Scheffler, C Kleinschnitz, ... European journal of neurology 28 (7), 2357-2366, 2021 | 18 | 2021 |
| Reduced vestibular perception thresholds in persistent postural-perceptual dizziness-a cross-sectional study S Wurthmann, D Holle, M Obermann, M Roesner, M Nsaka, A Scheffler, ... BMC neurology 21, 1-10, 2021 | 13 | 2021 |
| Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies M Nsaka, A Scheffler, S Wurthmann, H Schenk, C Kleinschnitz, M Glas, ... Brain and Behavior 12 (7), e2662, 2022 | 10 | 2022 |
| Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study H Schenk, D Holle, M Nsaka, C Kleinschnitz, M Glas, A Scheffler The Journal of Headache and Pain 23 (1), 55, 2022 | 8 | 2022 |
| Hypnic Headache–What do we know in 2022? D Lindner, A Scheffler, M Nsaka, D Holle-Lee Cephalalgia 43 (3), 03331024221148659, 2023 | 4 | 2023 |
| Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre … A Scheffler, P Wenzel, M Bendig, A Gendolla, J Basten, C Kleinschnitz, ... The Journal of Headache and Pain 25 (1), 2024 | | 2024 |
| Retrospektive Real-World-Analyse des Nebenwirkungsprofils von Erenumab über 12 Monate: Risiken für Nebenwirkungen? H Schenk, D Holle-Lee, M Nsaka, A Scheffler Nervenheilkunde 41 (05), V21, 2022 | | 2022 |
| Response to the Letter to the Editor by Arshad and Bronstein" Motion perception in vestibular migraine". S Wurthmann, S Naegel, M Nsaka, A Scheffler, C Kleinschnitz, D Holle, ... European Journal of Neurology 28 (11), 2021 | | 2021 |
| Response to the Letter to the Editor entitled" Motion perception in Vestibular Migraine". S Wurthmann, S Naegel, M Nsaka, A Scheffler, C Kleinschnitz, D Holle, ... European Journal of Neurology, 2021 | | 2021 |
| Erenumab in Highly Therapy-refractory Migraine Patients: First Real-world Evidence A Scheffler, O Messel, S Wurthmann, M Nsaka, C Kleinschnitz, M Glas, ... | | 2020 |
| Is a mandatory treatment break after a one-year prophylactic treatment with calcitonin gene-related peptide antibodies (receptor) monoclonal antibodies reasonable?: Real World … M Nsaka Dissertation, Duisburg, Essen, Universität Duisburg-Essen, 2022, 0 | | |
